sibeprenlimab
Asset
Monoclonal antibody targeting and inhibiting APRIL (TNFSF13) to reduce pathogenic antibody production.
- Stage
- Phase 2
- Modality
- Antibody
- Target
- Inflammation
- 3
- Indications
- 1
- Trial
- 1
- Developer
Indications
3Focal segmental glomerulosclerosis
Phase 2, Not yet recruiting, NCT07861113, clinicaltrials.gov, 7 Oct 2026
Minimal change disease
Phase 2, Not yet recruiting, NCT07861113, clinicaltrials.gov, 7 Oct 2026
Primary membranous nephropathy
Phase 2, Not yet recruiting, NCT07861113, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors3
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026, 1 source